CINV Corp Limited a U.K. company with cultivation assets in Africa, will combine its operations with Virtual Medical International Inc. Creating a vertically integrated cannabis company with one of the lowest costs of production globally.

CINV Corp is still scaling its operation in Zimbabwe, after delays caused by COVID-19, but remained resilient during the past 12 months while construction was delayed. Thanks to this acquisition CINV Corp will continue its vision as a pioneer in Africa that produces, high-grade EU-GMP THC medical flower at its 30,000 SQ FT facility in Zimbabwe. CINV Corp’s business model will make it the lowest cost producer, with the highest grade of product globally.

CINV Corp is not a simple cultivator of EU-GMP THC cannabis flower, it also engages in genetic research and development, this capability allows CINV Corp to develop a proprietary seed bank of desirable and effective cannabis strains. The plants will have traits that can include low water requirements, pest resistance and higher yields of rare cannabinoids such as THCV and CBG etc, which have a higher market value than traditional THC and CBD produce.

This acquisition will accelerate CINV Corp’s expansion plans. Following the successful execution of the transaction, the combined group of companies will operate under the Virtual Medical name with CINV Corp becoming a wholly-owned subsidiary headquartered in London.

The acquisition is expected to result in substantial benefits for Virtual Medical with CINV Corp’s medicinal cannabis THC focused cultivation facility in its portfolio of vertically integrated companies:

  • Establishes Virtual Medicals THC cultivation credentials and demonstrates the “seed-to- sale” value chain for both recreational and medicinal markets.
  • Provides access to pharmaceutical and clinical research entities with a high demand THC product that has as much as 5 times the value of traditional CBD products currently offered by VMI.
  • Opportunities for collaboration with VMI’s expert medical and scientific executive management team, to align CINV Corp R&D efforts that produce rare cannabinoids which have an increased efficacy for chronic disease and provide higher returns for investors and stakeholders.
  • Increases Virtual Medical’s reputation as a manufacturer of high-quality products on a large scale and provides access to European and global markets outside of the USA.

VMI have confirmed the appointment of Jon-Paul Doran, who was pleased to accept the role as President EMEA of the combined company, Jon-Paul the original co-founder of CINV Corp will continue to lead the new business after the acquisition, Jon-Paul Doran is a veteran in the financial markets who entered the cannabis industry in 2018. The combined company has a very strong board which includes Larson Elmore who will become Chief Executive Officer, DR. Daniel Reshef and DR Aubrey Oliver.

Non-Executive director positions will be held by Timothy Ambrose (CINV Corp COO), Philip Collin & Richard Collins.

CINV Corp CEO JP Doran commented on the acquisition saying “This acquisition really bears testament to the hard work carried out by my team, we are now in a position to assume our role as one of the most exciting and dominant cannabis cultivation companies globally. This position also rewards our loyal investors with a tremendous opportunity to see explosive growth with VMI.”

“We are very excited at this next chapter and look forward to delivering a world-class vertically integrated cannabis company”.

Larson Ellmore the CEO of the combined company said “The combination of Virtual Medical & CINV Corp is a game-changer in the U.S. cannabis industry. Our goal is to create through aggressive acquisition and expansion one of the largest public cannabis companies in the US in this Sector, Combining CINV Corp’s low cost of production, high-quality product grown in perfect natural conditions means we have no barrier to entry on any geographical market.”

The acquisition will provide a potential liquidity event for CINV Corp investors allowing them to liquidate or retain their shares and continue towards a higher growth trajectory in the combined company.

About Virtual Medical International

Virtual Medical International, (OTC: QEBR), through its wholly-owned subsidiary, has trademarked the brand name “Amsterdam Café: Welcome to Your Whole Health”™. The diversified, multi-channel business model is positioned to derive revenue from product sales through company-owned retail stores, franchise stores, domestic and international franchise activities, third-party contract manufacturing, e-commerce and corporate alignments.

Virtual Medical International’s business model is designed to help consumers improve the health and quality of their lives by making available an array of high quality, CBD-centric products consistent with a healthy lifestyle. To that end, Virtual Medical formed Amsterdam Café as a wholly-owned subsidiary to become a comprehensive, vertically integrated organization within the CBD whole health sector, with plans to acquire and open CDB Stores across the U.S.A. and Europe.

For further information contact:
Larson Elmore Phone: +1 (216) 345-4567
Email: [email protected]

About CINV Corp:

CINV Corp is a London based company with rapidly expanding production operations in Africa. CINV Corp has acquired licenses in Africa to meet the global demand for an effective medicinal cannabis product supplied to the wholesale pharmaceutical industry.

CINV Corp intends to become world leaders in the production of medicinal quality cannabis, supplying extracts and produce such as GMP-Flower, GMP-Oil to the pharmaceutical industry as an API (Active Pharmaceutical Ingredient) to meet the increasing global demand for a premium medicinal cannabis product that transforms lives. With a combination of research, development, cultivating, growing and manufacturing CINV Corp’s mission is to advance the medical extracts, related products and sector as a whole by educating the Zimbabwe community and developing products that are safe, effective and affordable for export.

For further information contact:
Jon-Paul Doran Phone: +44 (0)20 7043 1541
Email: [email protected]

Press enquiries contact:
Jonathan Millbank Marketing Director Phone: +44 (0)20 7043 1541
Email: [email protected]